|
Patient-reported outcomes and quality of life in ALTA: The randomized phase 2 study of brigatinib (BRG) in advanced ALK+ non–small cell lung cancer (NSCLC). |
|
|
Honoraria - Bristol-Myers Squibb; Genentech/Roche; Lilly/ImClone |
Consulting or Advisory Role - Abbott Biotherapeutics; ARIAD; Bayer/Onyx; Bristol-Myers Squibb; Cancer Support Community; Celgene; Clarient; Clovis Oncology; Genentech/Roche; Lilly/ImClone; Merck |
Research Funding - Advantagene (Inst); Ariad (Inst); Celgene (Inst); Clovis Oncology (Inst); Genentech/Roche (Inst); GlaxoSmithKline (Inst); Inovio Pharmaceuticals (Inst); Merck (Inst); Stem CentRx (Inst) |
|
|
|
Stock and Other Ownership Interests - ARIAD |
|
|
|
Stock and Other Ownership Interests - ARIAD |
Consulting or Advisory Role - ARIAD |
|
|
|
|
Stock and Other Ownership Interests - ARIAD |
|
|
No Relationships to Disclose |
|
|
|
Research Funding - Evidera |
|
|
|
Stock and Other Ownership Interests - Pfizer |